Can a single stem cell infusion rewire the brain after stroke?

NCT ID NCT03545607

Terminated Disease control Sponsor: Healios K.K. Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a single infusion of MultiStem, an experimental stem cell product, can improve recovery in adults who have had a moderate-to-severe ischemic stroke within the past 18 to 36 hours. The study compares the stem cell treatment against a placebo to see if it reduces long-term disability and improves daily functioning. Participants are adults with a confirmed stroke affecting the brain's cortex, and the main goal is to assess their level of disability three months later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MultiStem, an experimental allogeneic adult stem cell product given as a single intravenous infusion
What this could lead to: If successful, this could provide a new treatment to reduce disability and improve functional recovery after a stroke, potentially helping many patients regain independence.
What could go wrong: This is a phase 3 trial, but the treatment is still experimental. It may not prove more effective than placebo, and there are risks associated with any infusion, including allergic reactions or immune responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE

Contacts and locations

Locations

Athersys Investigational Site 101

Houston, Texas, 77030, United States
Athersys Investigational Site 102

Portland, Oregon, 97239, United States
Athersys Investigational Site 103

Augusta, Georgia, 30912, United States
Athersys Investigational Site 104

Cleveland, Ohio, 44195, United States
Athersys Investigational Site 105

Houston, Texas, 77030, United States
Athersys Investigational Site 106

Pittsburgh, Pennsylvania, 15213, United States
Athersys Investigational Site 107

Hershey, Pennsylvania, 17033, United States
Athersys Investigational Site 108

Miami, Florida, 33136, United States
Athersys Investigational Site 109

Akron, Ohio, 44304, United States
Athersys Investigational Site 110

Salt Lake City, Utah, 84112, United States
Athersys Investigational Site 111

Jackson, Mississippi, 39216, United States
Athersys Investigational Site 113

Boston, Massachusetts, 02114, United States
Athersys Investigational Site 115

Chattanooga, Tennessee, 37403, United States
Athersys Investigational Site 118

Columbia, South Carolina, 29203, United States
Athersys Investigational Site 119

Kansas City, Kansas, 66160, United States
Athersys Investigational Site 121

Chicago, Illinois, 60201, United States
Athersys Investigational Site 122

Palo Alto, California, 94304, United States
Athersys Investigational Site 124

Wichita, Kansas, 67214, United States
Athersys Investigational Site 125

Minneapolis, Minnesota, 55455, United States
Athersys Investigational Site 127

Sacramento, California, 95817, United States
Athersys Investigational Site 128

Phoenix, Arizona, 85013, United States
Athersys Investigational Site 129

Clearwater, Florida, 33756, United States
Athersys Investigational Site 130

Toledo, Ohio, 43606, United States
Athersys Investigational Site 601

Taipei, 10002, Taiwan
Athersys Investigational Site 602

Taoyuan City, 33305, Taiwan
Athersys Investigational Site 603

Taichung, 40402, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.